Shares of Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report) were up 3.3% during mid-day trading on Wednesday . The company traded as high as $0.6569 and last traded at $0.6493. 97,306 shares were traded during trading, a decline of 99% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.6286.
Emerald Bioscience Stock Performance
The business has a 50 day simple moving average of $0.73. The firm has a market cap of $174.06 million, a PE ratio of -8.12 and a beta of 0.43. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.43.
About Emerald Bioscience
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
Featured Articles
- Five stocks we like better than Emerald Bioscience
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
